MAVYRET APPROVAL SET TO CHANGE THE COMPETITIVE SCENARIO IN HEPATITIS C TREATMENT MARKET by JohnPattersonIn August 2017, the US FDA approved Abbvie’s drug Mavyret for treating all six forms of Hepatitis C. With 2.7 million to 3.9 million patients, the market is currently being ruled by Gilead through a combination of sofosbuvir, velpatasvir and voxilaprevir. The treatment period of Abbvie is also less than Gilead, with the former curing the disease in eight weeks as compared to Gilead’s 12 weeks timeline.To gain strong market share in the huge market, Abbvie plans to launch the Mavyret drug at a discount to Gilead’s Harvoni, thus leading to a price war. Comparison between prices of two drugs is $13,200 monthly price for Mavyret as compared to $31,500 per month Harvoni.Medicines from Johnson & Johnson, Merck & Co. Inc., and Vertex Pharmaceuticals Inc, which once ruled the global hepatitis C market by generating billions of dollars, are almost phased out.Further, promising drug trials are being conducted by other players with several interventions in pipeline. Most of the trials are led by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment shifted towards combination regimens largely without the use of interferon/ ribavirin, driven by high tolerability. To identify the drugs and treatment options in progress and understand emergence of market trends, please visit our new report on Global Hepatitis C therapeutics-https://www.reportmarkets.com/20038-PharmaPoint–Hepatitis-C-Virus–HCV–Therapeutics—Global-Drug-Forecast-and-Market-Analysis-to-2025Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025 Summary The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. Scope – Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered. – Topline hepatitis C market revenue from 2015-2025.Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model. It also answers the following questions– Favourable R&D strategies to remain competitive in future hepatitis C marketplace?- Epidemiological Forecast of HCV to 2025?- Impact of pan-genotypic DAA regimens on global hepatitis C industry?- Enrolment dynamics and their response based on changing treatment rates and growth in cure rates?The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global hepatitis C market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis C market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.For full Report on Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025 Please Contact :JohnPattersonsales@reportmarkets.com+19285924068Article Source: eArticlesOnline.com